medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2015, Number 3

<< Back Next >>

Ann Hepatol 2015; 14 (3)

IFNL3 polymorphisms and HCV infection in patients with beta thalassemia

Origa R, Marceddu G, Danjou F, Perseu L, Satta S, Demartis FR, Piga A, Longo F, Maria-Eliana Lai, Vacquer S, Galanello R

Language: English
References: 28
Page: 389-395
PDF size: 105.79 Kb.


ABSTRACT

Background and relationale for the study. Genome-wide association studies have identified host genetic variation to be critical for spontaneous clearance and treatment response in patients infected with hepatitis C virus. Recently, the role of the IFNL3 polymorphisms in influencing the spontaneous clearance of HCV, the response to interferon and the progression of liver fibrosis, was also demonstrated in patients with thalassemia major infected by genotype 1b. In the present study we retrospectively analyzed 368 anti-HCV positive patients with beta-thalassemia at two Italian major centers in Cagliari and Torino. Results. C/C variant of polymorphism rs12979860 was related to response to interferon treatment and, above all, to spontaneous clearance of the virus. However, the positive predictive power was stronger for viral persistence than spontaneous clearance and in such respect the TT allele was more predictive than CC. The methylation associated polymorphism rs4803221 had independent effects with respect to rs12979860 and the haplotype tagged by SNP rs12979860 and rs4803221 significantly could improve the viral clearance prediction in infected patients. Neither necroinflammation or bilirubin values in the chronic phase of the hepatitis C were related to IFNL3 polymorphisms. No relation among IFNL3 polymorphisms and fibrosis stage directly shown by the liver biopsy was found. Conclusions. Also in thalassemia the SNPs on chromosome 19q13 closely associates with spontaneous and treatment-induced HCV clearance. The viral clearance prediction is significantly improved by the haplotype tagged by SNP rs12979860 and rs4803221. Neither necroinflammation, bilirubin values or fibrosis stage seem to be related to IFNL3 polymorphisms.


REFERENCES

  1. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, et al. Genetic variation in IFNL3 predicts hepatitis C treatment-induced viral clearance. Nature 2009;461: 399-401.

  2. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, et al. IFNL3 is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-4.

  3. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C, Kidd J, et al. Genetic variation in IFNL3 and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.

  4. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, et al. Genome-wide association of IFNL3 with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.

  5. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, et al. Genetic variation in IFNL3 is associated with chronic hepatitis C and treatment failure: a genome- wide association study. Gastroenterology 2010; 138: 1338-45, 1345.e1-7.

  6. Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, Yamashita T, et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139: 499-509.

  7. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, Hong L, et al. IFNL3 genotype is associated with differential expression of intrahepatic interferonstimulated genes in patients with chronic hepatitis C. Hepatology 2010; 52: 1888-96.

  8. Sarrazin C, Susser S, Doehring A, Lange CM, Müller T, Schlecker C, Herrmann E, et al. Importance of IFNL3 gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 2011; 54: 415-21.

  9. Abe H, Ochi H, Maekawa T, Hayes CN, Tsuge M, Miki D, Mitsui F, et al. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol 2010; 53: 439-43.

  10. Falleti E, Bitetto D, Fabris C, Cussigh A, Fornasiere E, Cmet S, Fumolo E, et al. Role of Interleukin 28B rs12979860 C/T Polymorphism on the Histological Outcome of Chronic Hepatitis C: Relationship with Gender and Viral Genotype. J Clin Immunol 2011; 31: 891-9.

  11. Fabris C, Falleti E, Cussigh A, Bitetto D, Fontanini E, Bignulin S, Cmet S, et al. IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: Role in the 395 IFNL3 polymorphisms and HCV infection in patients with beta thalassemia. , 2015; 14 (3): 389-395 course of chronic viral hepatitis and the development of HCC. J Hepatol 2011; 54: 716-22.

  12. Marabita F, Aghemo A, De Nicola S, Rumi MG, Cheroni C, Scavelli R, Crimi M, et al. Genetic variation in the interleukin- 28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology 2011; 54: 1127-34.

  13. Thompson AJ, Clark PJ, Fellay J, Muir AJ, Tillmann HL, Patel K, Naggie S, et al. IFNL3 genotype is not associated with advanced hepatic fibrosis in chronic hepatitis C patients enrolled in the IDEAL study [abstract]. Hepatology 2010; 52(Suppl. 1): 437A.

  14. Agúndez JA, García-Martin E, Maestro ML, Cuenca F, Martínez C, Ortega L, Carballo M, et al. Relation of IFNL3 gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver disease. PLoS One 2012; 7: e37998.

  15. Tillmann HL, Thompson AJ, Patel K, Wiese M, Tenckhoff H, Nischalke HD, Lokhnygina Y, et al. A polymorphism near IFNL3 is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010; 139: 1586-92, 1592.e1.

  16. di Iulio J, Ciuffi A, Fitzmaurice K, Kelleher D, Rotger M, Fellay J, Martinez R, et al. Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance. Hepatology 2011; 53: 1446-54.

  17. Smith KR, Suppiah V, O’Connor K, Berg T, Weltman M, Abate ML, Spengler U, et al. Identification of improved IFNL3 SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Med 2011; 3: 57.

  18. Di Marco V, Bronte F, Calvaruso V, Capra M, Borsellino Z, Maggio A, Renda MC, et al. IFNL3 polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. Haematologica 2012; 97: 679-86.

  19. Velati C, Romanò L, Fomiatti L, Baruffi L, Zanetti AR; SIMTI Research Group. Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey. Transfusion 2008; 48: 2205-13.

  20. Prati D, Zanella A, Farma E, De Mattei C, Bosoni P, Zappa M, Picone A, et al. A multicenter prospective study on the risk of acquiring liver disease in anti-hepatitis C virus negative patients affected from homozygous beta-thalassemia. Blood 1998; 92: 3460-4.

  21. Prati D, Maggioni M, Milani S, Cerino M, Cianciulli P, Coggi G, Forni GL, et al. Clinical and histological characterization of liver disease in patients with transfusion-dependent beta-thalassemia. A multicenter study of 117 cases. Haematologica 2004: 89: 1179-86.

  22. Restivo Pantalone G, Renda D, Valenza F, D’Amato F, Vitrano A, Cassarà F, Rigano P, et al. Hepatocellular carcinoma in patients with thalassaemia syndromes: clinical characteristics and outcome in a long term single centre experience. Br J Haematol 2010; 150: 245-7.

  23. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-20.

  24. Abe H, Ochi H, Maekawa T, Hayes CN, Tsuge M, Miki D, Mitsui F, et al. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol 2010; 53: 439-43.

  25. Angelucci E, Muretto P, Nicolucci A, Baronciani D, Erer B, Gaziev J, Ripalti M, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 2002; 100: 17-21.

  26. Tzetis M, Kanavakis E, Tsezou A, Ladis V, Pateraki E, Georgakopoulou T, Kavazarakis E, et al. Gilbert syndrome associated with beta-thalassemia. Pediatr Hematol Oncol 2001; 18: 477-84.

  27. Origa R, Galanello R, Perseu L, Tavazzi D, Domenica Cappellini M, Terenzani L, Forni GL, et al. Cholelithiasis in thalassemia major. Eur J Haematol 2009; 82: 22-5.

  28. Booth D, George J. Loss of function of the new interferon IFN-λ4 may confer protection from hepatitis C. Nat Genet 2013; 45: 119-20.




2020     |     www.medigraphic.com